multinational study: Brivanib -oral- (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT)-- ASCO Meeting Abstract Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, June 12, 2011

multinational study: Brivanib -oral- (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT)-- ASCO Meeting Abstract



Background:
Brivanib (B) is an oral once daily selective dual inhibitor of FGF and VEGF signaling currently in phase III development for advanced hepatocellular carcinoma and colorectal cancer.



"Biomarker exploration with potential for enrichment continues; breast and ovarian cohorts have been added to the trial."

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.